IRCT2012102111194N1已完成2 期
Evaluation of metformin effect on progression of autosomal dominant polycystic kidney disease; a clinical trial
Vice-chancellor for research,Tehran University of Medical Science0 个研究点目标入组 30 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 30
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 years 至 60 years（—）
- 性别
- All
入选标准
- •Inclusion: Known case of Autosomal dominant polycystic kidney disease (by sonography); age between 18-60 years old; GFR>=60 cc/min.
- •Exclusion: history of diabetes mellitus; history of heart failure; history of liver failure
排除标准
- 未提供
研究者
相似试验
已完成
不适用
Effect of Metformin (Drug)in Patients With Cryptogenic Cirrhosis (Liver Disease) With DiabetesCTRI/2018/03/012814Institute of liver and Biliary Sciences86
进行中（未招募）
1 期
Study to evaluate the effect of metformin in the prevention of hyperglycemiain HR[+]/HER2[–] PIK3CA-mutated advanced breast cancer patients treatedwith alpelisib plus endocrine therapy. The Metallica study.Study to evaluate the effect of metformin in the prevention of hyperglycemiain HR[+]/HER2[–] PIK3CA-mutated advanced breast cancer patients treatedwith alpelisib plus endocrine therapy. The Metallica study.CTIS2024-511295-33-00Medica Scientia Innovation Research S.L.88
招募中
3 期
The effect of metformin in patients with ovarian cancerSerum CA125 changes.Elevated cancer antigen 125 [CA 125]R97.1IRCT20120922010901N7Tabriz University of Medical Sciences90
尚未招募
2 期
Comparison of Metformin therapy with Placebo therapy on progression of disease in the patients with Autosomal Dominant Polycystic Kidney Disease.CTRI/2024/06/069541IPGMER and SSKM hospital
已完成
不适用
Metformin as an adjunct therapy in type 1 diabetesDiabetes 1.Insulin-dependent diabetes mellitusIRCT2016120110988N5Vice Chancellor for research of Tehran University of Medical Sciences29